FGF-22 Antibody (435008) [Alexa Fluor® 647]

• Reactivity: Hu
• Applications: WB, B/N
• Clone: 435008
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 647

FGF-22 Antibody (435008) [Alexa Fluor® 647] Summary

• Immunogen: E. coli-derived recombinant human FGF-22
  Thr23-Ser170
  Accession # Q9HCT0
• Specificity: Detects human FGF-22 in direct ELISAs and Western blots. In Western blots, no cross-reactivity with recombinant human (rh) FGF-basic, rhFGF-3, -4, -5, -6, -7, -9, -10, -11, -12, -13, -16, -17, -18, -19, -20, -21, -23, recombinant mouse (rm) FGF-
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Neutralization
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for FGF-22 Antibody (435008) [Alexa Fluor® 647]

• FGF22
• FGF-22
• fibroblast growth factor 22

Background

Fibroblast growth factor-22 (FGF-22) is a 23 kDa, non-glycosylated member of the FGF-7 subfamily, from the FGF family of heparin-binding growth factors (1‑3). The human FGF-22 precursor is 170 amino acids (aa) in length, and contains a 22 aa signal sequence with a 148 aa mature region (4‑6). The mature region shows a centrally-placed, 120 aa beta -trefoil region (aa 43‑168) that is characteristic of all FGF family members. Human FGF-22 potentially has one alternate splice form. This isoform is 129 aa in length, and shows a 31 aa substitution for the first N-terminal 72 aa of the standard, or long, form (7). There is no information related to its possible function. Mature human FGF-22 is 86% aa identical to mouse FGF-22, with the mouse molecule showing a 9 aa deletion at the N-terminus (5). FGF-22 is synthesized by at least three cell types; keratinocytes, neurons, and skeletal muscle myotubes (4, 8, 9). In neurons and myotubes, FGF-22 is presumed to function as an organizer of the presynaptic apparatus. Expressed by postsynaptic (or target) cells, FGF-22 is believed to bind to FGF R2b on the surface of innervating processes, resulting in synaptic vesicle clustering, organization, and neurite branching (8, 10). Although FGF-22 is assumed to be secreted, little can be found in expressing cell culture media. Presumably, it is bound to 34 kDa FGF-BP1, which is a molecule described as typically associated with cell membrane proteoglycans (6, 11). Thus, following secretion, FGF-22 could quickly be immobilized by FGF-BP1, only to be released at a later time, or aided by FGF-BP1 in its interaction with FGF R2b (6, 10, 11).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • Q9HCT0()